CL2015003512A1 - Uso de dianhidrogalactitol y análogos y derivados del mismo para tratar glioma maligno recurrente o tumor cerebral secundario progresivo - Google Patents

Uso de dianhidrogalactitol y análogos y derivados del mismo para tratar glioma maligno recurrente o tumor cerebral secundario progresivo

Info

Publication number
CL2015003512A1
CL2015003512A1 CL2015003512A CL2015003512A CL2015003512A1 CL 2015003512 A1 CL2015003512 A1 CL 2015003512A1 CL 2015003512 A CL2015003512 A CL 2015003512A CL 2015003512 A CL2015003512 A CL 2015003512A CL 2015003512 A1 CL2015003512 A1 CL 2015003512A1
Authority
CL
Chile
Prior art keywords
derivatives
brain tumor
dianhydrogalactitol
analogues
secondary brain
Prior art date
Application number
CL2015003512A
Other languages
English (en)
Inventor
Kent C Shih
Anne Steino
Richard Schwartz
Sareth Kanekal
Howard A Burris Iii
Jeffrey Bacha
William Garner
Dennis M Brown
Original Assignee
Del Mar Pharmaceuticals
Dennis M Brown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Del Mar Pharmaceuticals, Dennis M Brown filed Critical Del Mar Pharmaceuticals
Publication of CL2015003512A1 publication Critical patent/CL2015003512A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)

Abstract

USO DE DERIVADOS DE HEXITOL PARA TRATAR GLIOMA MALIGNO RECURRENTE O TUMOR CEREBRAL SECUNDARIO PROGRESIVO; COMPOSICION FARMACEUTICA; COMBINACION FARMACEUTICA; KIT FARMACEUTICO.
CL2015003512A 2013-05-31 2015-11-30 Uso de dianhidrogalactitol y análogos y derivados del mismo para tratar glioma maligno recurrente o tumor cerebral secundario progresivo CL2015003512A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361829739P 2013-05-31 2013-05-31

Publications (1)

Publication Number Publication Date
CL2015003512A1 true CL2015003512A1 (es) 2016-09-09

Family

ID=51989551

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003512A CL2015003512A1 (es) 2013-05-31 2015-11-30 Uso de dianhidrogalactitol y análogos y derivados del mismo para tratar glioma maligno recurrente o tumor cerebral secundario progresivo

Country Status (14)

Country Link
US (1) US11026914B2 (es)
EP (1) EP3003321A4 (es)
JP (3) JP2016520622A (es)
KR (4) KR20230124765A (es)
CN (1) CN105579044A (es)
AU (2) AU2014273911B2 (es)
BR (1) BR112015029989A2 (es)
CA (1) CA2914025C (es)
CL (1) CL2015003512A1 (es)
IL (1) IL242853B (es)
MX (1) MX2015016404A (es)
SG (1) SG11201509837QA (es)
TW (1) TW201536278A (es)
WO (1) WO2014194312A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014179528A2 (en) * 2013-05-01 2014-11-06 Brown Dennis M Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
WO2016138542A1 (en) * 2015-02-28 2016-09-01 Cyprus Therapeutics, Inc. Methods for inhibiting tumors and drug resistance
US20190091195A1 (en) * 2015-09-10 2019-03-28 Del Mar Pharmaceuticals Use of dianhydrogalactitol and derivatives thereof in the treatment of glioblastoma, lung cancer, and ovarian cancer
JP7112327B2 (ja) * 2015-12-29 2022-08-03 アウトルック セラピューティクス，インコーポレイティド ベバシズマブの緩衝された製剤
US20200062839A1 (en) * 2017-05-01 2020-02-27 Del Mar Pharmaceuticals (Bc) Ltd. Use of dianhydrogalactitol or analogs and derivatives in combination with vegf inhibitors to treat cancer
US20180353446A1 (en) * 2017-06-07 2018-12-13 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing cancer
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
CA3067026A1 (en) * 2017-06-12 2018-12-20 Stanislaw R. Burzynski Use of antineoplastons to treat leptomeningeal disease
SG11202002105WA (en) * 2017-09-11 2020-04-29 Atossa Therapeutics Inc Methods for making and using endoxifen
WO2019211708A1 (en) * 2018-05-04 2019-11-07 Kashiv Biosciences, Llc Stable pharmaceutical compositions of dianhydrogalactitol
CN109337884B9 (zh) * 2018-12-21 2021-10-29 中国农业科学院北京畜牧兽医研究所 一种丙酮酸激酶基因及其应用
KR102415193B1 (ko) 2020-04-16 2022-06-29 사회복지법인 삼성생명공익재단 벤즈브로마론을 유효성분으로 포함하는 뇌암 예방 또는 치료용 약학 조성물
WO2021252432A1 (en) * 2020-06-08 2021-12-16 Neonc Technologies, Inc. Compositions and methods for delivering polynucleotides
CN114796522A (zh) * 2022-01-06 2022-07-29 宁波大学 一种靶向线粒体放大氧化应激的新型抗肿瘤纳米药物
WO2024039764A2 (en) * 2022-08-17 2024-02-22 Ohio State Innovation Foundation Epitranscriptomic analysis of glioma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4785077A (en) 1986-05-05 1988-11-15 Scripps Clinic And Research Foundation Substantially pure cytotoxicity triggering factor
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5294430A (en) * 1988-09-12 1994-03-15 University Of Rochester Use of dithiocarbamates to treat myelosuppression
MX2013001858A (es) * 2010-08-18 2013-09-13 Del Mar Pharmaceuticals Composiciones y métodos para mejorar el beneficio terapéutico de los compuestos quimicos administrados de manera suboptima que incluyen hexitoles substituidos tal como dianhidrogalactitol y diacetildianhidrogalactitol.
CN115778934A (zh) 2012-01-20 2023-03-14 德玛公司 经取代的己糖醇类用于治疗恶性肿瘤的用途
WO2013169600A1 (en) * 2012-05-09 2013-11-14 Delmar Pharmaceuticals Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies

Also Published As

Publication number Publication date
US20160158186A1 (en) 2016-06-09
KR20220080199A (ko) 2022-06-14
MX2015016404A (es) 2016-09-28
SG11201509837QA (en) 2015-12-30
JP2016520622A (ja) 2016-07-14
CN105579044A (zh) 2016-05-11
IL242853B (en) 2022-03-01
US11026914B2 (en) 2021-06-08
BR112015029989A2 (pt) 2017-08-22
KR20210100754A (ko) 2021-08-17
AU2019283893A1 (en) 2020-01-23
WO2014194312A3 (en) 2015-02-05
AU2019283893B2 (en) 2022-03-24
CA2914025A1 (en) 2014-12-04
TW201536278A (zh) 2015-10-01
AU2014273911B2 (en) 2019-09-19
EP3003321A2 (en) 2016-04-13
JP2022088616A (ja) 2022-06-14
CA2914025C (en) 2023-03-07
KR20230124765A (ko) 2023-08-25
KR20160065776A (ko) 2016-06-09
EP3003321A4 (en) 2017-01-18
AU2014273911A1 (en) 2016-01-07
JP2020079259A (ja) 2020-05-28
WO2014194312A2 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
CL2015003512A1 (es) Uso de dianhidrogalactitol y análogos y derivados del mismo para tratar glioma maligno recurrente o tumor cerebral secundario progresivo
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
CL2018000293A1 (es) Compuestos heterocíclicos útiles como moduladores de factor de necrosis tumoral (tnf) alfa
CL2018000978A1 (es) Macrociclos peptídicos contra acinetobacter baumannii
EA201790737A1 (ru) Комбинированная терапия
CL2015002658A1 (es) Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
ECSP15026557A (es) Compuestos y sus métodos de empleo
DOP2016000153A (es) Anticuerpos y fragmentos anti-vista
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
NZ722326A (en) Tricyclic compounds as anticancer agents
CL2017001046A1 (es) Inhibidoes del bromodominio
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
IL242386B (en) Use of Aribolin and Lavetinib as a combination therapy for cancer treatment
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
UY35747A (es) Derivados sustituidos de fenilalanina